WO2000065053A3 - Compositions and methods for therapy and diagnosis of head/neck and lung squamous cell carcinoma - Google Patents

Compositions and methods for therapy and diagnosis of head/neck and lung squamous cell carcinoma Download PDF

Info

Publication number
WO2000065053A3
WO2000065053A3 PCT/US2000/010687 US0010687W WO0065053A3 WO 2000065053 A3 WO2000065053 A3 WO 2000065053A3 US 0010687 W US0010687 W US 0010687W WO 0065053 A3 WO0065053 A3 WO 0065053A3
Authority
WO
WIPO (PCT)
Prior art keywords
head
neck
compositions
diagnosis
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/010687
Other languages
French (fr)
Other versions
WO2000065053A2 (en
Inventor
Tongtong Wang
Davin C Dillon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Priority to AU46515/00A priority Critical patent/AU4651500A/en
Priority to EP00928254A priority patent/EP1173570A2/en
Priority to CA002370482A priority patent/CA2370482A1/en
Publication of WO2000065053A2 publication Critical patent/WO2000065053A2/en
Publication of WO2000065053A3 publication Critical patent/WO2000065053A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Compositions and methods for the therapy and diagnosis of cancer, such as head and neck cancer and lung cancer, are disclosed. Compositions may comprise one or more head and neck tumor proteins, immunogenic portions thereof or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a head and neck tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as head and neck cancer and lung cancer. Diagnostic methods based on detecting a head and neck tumor protein, or mRNA encoding such a protein, in a sample are also provided.
PCT/US2000/010687 1999-04-23 2000-04-21 Compositions and methods for therapy and diagnosis of head/neck and lung squamous cell carcinoma Ceased WO2000065053A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU46515/00A AU4651500A (en) 1999-04-23 2000-04-21 Compositions and methods for therapy and diagnosis of head/neck and lung squamous cell carcinoma
EP00928254A EP1173570A2 (en) 1999-04-23 2000-04-21 Compositions and methods for therapy and diagnosis of head/neck and lung squamous cell carcinoma
CA002370482A CA2370482A1 (en) 1999-04-23 2000-04-21 Compositions and methods for therapy and diagnosis of head/neck and lung squamous cell carcinoma

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13090699P 1999-04-23 1999-04-23
US60/130,906 1999-04-23
US09/533,870 2000-04-20

Publications (2)

Publication Number Publication Date
WO2000065053A2 WO2000065053A2 (en) 2000-11-02
WO2000065053A3 true WO2000065053A3 (en) 2001-07-19

Family

ID=22446911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010687 Ceased WO2000065053A2 (en) 1999-04-23 2000-04-21 Compositions and methods for therapy and diagnosis of head/neck and lung squamous cell carcinoma

Country Status (4)

Country Link
EP (1) EP1173570A2 (en)
AU (1) AU4651500A (en)
CA (1) CA2370482A1 (en)
WO (1) WO2000065053A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002353972A1 (en) * 2001-11-02 2003-05-19 Pfizer Products Inc. Lung cancer therapeutics and diagnostics
CN103397096A (en) * 2013-08-05 2013-11-20 浙江天科高新技术发展有限公司 Biomarker for detecting hepatocellular carcinoma and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
US5776676A (en) * 1992-05-20 1998-07-07 The United States Of America As Represented By The Department Of Health And Human Services HME1 nucleic acids and probes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776676A (en) * 1992-05-20 1998-07-07 The United States Of America As Represented By The Department Of Health And Human Services HME1 nucleic acids and probes
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AE KISIELEWSKI ET AL.: "Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck", ONCOGENE, vol. 17, no. 1, 9 July 1998 (1998-07-09), ISSN:0950-9232, pages 83 - 91, XP000953059 *
DB VILLARET ET AL.: "Identification of genes overexpressed in head and neck squamous cel carcinoma using a combination of complementary DNA subtraction and microarray analysis", THE LARYNGOSCOPE, vol. 110, no. 3, March 2000 (2000-03-01), ISSN:0023-852X, pages 374 - 381, XP000953135 *
G CHAN ET AL.: "Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck", CANCER RESEARCH, vol. 59, no. 3, 1 March 1999 (1999-03-01), MD US, pages 991 - 994, XP002151072 *

Also Published As

Publication number Publication date
CA2370482A1 (en) 2000-11-02
EP1173570A2 (en) 2002-01-23
AU4651500A (en) 2000-11-10
WO2000065053A2 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2000004149A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2001096388A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001096390A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2001034802A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001075171A3 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002083070A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002004514A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001073027A3 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2000052165A3 (en) Compositions and methods for breast cancer therapy and diagnosis
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001057207A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001051513A3 (en) Ovarian tumor-associated sequences
WO2002002623A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001070976A3 (en) Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
WO2001073031A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2370482

Country of ref document: CA

Ref country code: JP

Ref document number: 2000 614389

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2370482

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000928254

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000928254

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000928254

Country of ref document: EP